Explore our
portfolio of Niche Generic and Differentiated Finished Formulations for Animal Health
Milbemycin plus Praziquantel Chewable Tablets
| Therapeutic category | Anti Parasitic |
| Product Name | Milbemycin plus Praziquantel Chewable tablets |
| Dosage form | Chewable Tablets |
| Strength | 2.5/25 mg & 12.5/125mg (Dogs) & 4/10mg & 16/40mg (Cats) |
| IP and Exclusivity | Expired |
| Emerging Market | Dossier Available from GMP approved facility |
| Regulated market – Stage and Next steps | Lab Scale Development completed (EU); Technology Transfer and Bioequivalence study |
| Commercialization Support for regulated market | Supply form EU GMP approved facility |
| Unique Selling Points (USPs) | Palatable chewable bioequivalent formulation |
Oclacitinib Chewable Tablets
| Therapeutic category | Immunomodulator |
| Product Name | Oclacitinib Chewable tablets |
| Dosage form | Palatable Chewable Soft Chewable Tablets |
| Strength | 3.6 mg, 5.4 mg & 16mg (Dogs) |
| IP and Exclusivity | Expired |
| Emerging Market | Dossier Available from GMP approved facility |
| Regulated market – Stage and Next steps | Lab Scale Development completed (US & EU); Technology Transfer and Bioequivalence study |
| Commercialization Support for regulated market | Supply form USFDA & EU GMP approved facility |
| Unique Selling Points (USPs) | No generics worldwide |
Robenacoxib Injection
| Therapeutic category | NSAID (Pain Category) |
| Product Name | Robenacoxib Injection |
| Dosage form | Injection |
| Strength | 20mg/ml (Dogs & Cats) |
| IP and Exclusivity | Expired |
| Emerging Market | Dossier Available from GMP approved facility |
| Regulated market – Stage and Next steps | Lab Scale Development completed (EU); Technology Transfer |
| Commercialization Support for regulated market | Supply form EU GMP approved facility |
| Unique Selling Points (USPs) | No generics worldwide |
Robenacoxib Chewable Tablets
| Therapeutic category | NSAID (Pain Category) |
| Product Name | Robenacoxib Chewable tablets |
| Dosage form | Palatable Chewable Tablets |
| Strength | 6mg (Cats) |
| IP and Exclusivity | Expired |
| Emerging Market | Dossier Available from GMP approved facility |
| Regulated market – Stage and Next steps | Lab Scale Development completed (US & EU); Technology Transfer and Bioequivalence study |
| Commercialization Support for regulated market | Supply form USFDA & EU GMP approved facility |
| Unique Selling Points (USPs) | No generics worldwide |
Gamithromycin Injection
| Therapeutic category | Antibiotic |
| Product Name | Gamithromycin Injection |
| Dosage form | Injection |
| Strength | 150mg/ml (Cattle) |
| IP and Exclusivity | Expired |
| Emerging Market | Dossier Available from GMP approved facility |
| Regulated market – Stage and Next steps | Lab Scale Development completed (EU); Technology Transfer |
| Commercialization Support for regulated market | Supply form EU GMP approved facility |
| Unique Selling Points (USPs) | No generics worldwide |
Tulathromycin Injection
| Therapeutic category | Antibiotic |
| Product Name | Tulathromycin Injection |
| Dosage form | Injection |
| Strength | 100mg/ml (Cattle) |
| IP and Exclusivity | Expired |
| Emerging Market | Dossier Available from GMP approved facility |
| Regulated market – Stage and Next steps | Lab Scale Development completed (EU); Technology Transfer |
| Commercialization Support for regulated market | Supply form USFDA & EU GMP approved facility |
| Unique Selling Points (USPs) | High Value generic |
Florfenicol plus Flunixin Injection
| Therapeutic category | Antibiotic |
| Product Name | Florfenicol plus Flunixin Injection |
| Dosage form | Injection |
| Strength | 300/16.5mg per ml (Cattle) |
| IP and Exclusivity | Expired |
| Emerging Market | Dossier Available from GMP approved facility |
| Regulated market – Stage and Next steps | Lab Scale Development completed (EU); Technology Transfer |
| Commercialization Support for regulated market | Supply form EU GMP approved facility |
| Unique Selling Points (USPs) | No generics worldwide |
Florfenicol plus Meloxicam Injection
| Therapeutic category | Antibiotic |
| Product Name | Florfenicol plus Meloxicam Injection |
| Dosage form | Injection |
| Strength | 400/5mg per ml (Cattle) |
| IP and Exclusivity | Expired |
| Emerging Market | Dossier Available from GMP approved facility |
| Regulated market – Stage and Next steps | Lab Scale Development completed (EU); Technology Transfer |
| Commercialization Support for regulated market | Supply form EU GMP approved facility |
| Unique Selling Points (USPs) | No generics worldwide |
